A) Risperdal B) Geodon C) Zyprexa D) Prolixin
A) Invega B) Zyprexa C) Abilify D) Clozaril
A) Abilify B) Invega C) Seroquel D) Zyprexa
A) Seroquel B) Abilify C) Risperdal D) Zyprexa
A) Risperdal B) Abilify C) Seroquel D) Geodon
A) Clozapine B) Ziprasidone C) Olanzapine D) Quetiapine
A) Ziprasidone B) Paliperidone C) Aripriprazole D) Risperidone
A) Clozaril B) Seroquel C) Geodon D) Risperdal
A) Aripiprazole B) Paliperidone C) Ziprasidone D) Clozapine
A) Olazapine B) Paliperidone C) Quetiapine D) Risperdone
A) Risperidone and Paliperidone B) Aripiprazole and Paliperidone C) Clozapine and Aripiprazole D) Clozapine and Risperadone
A) 2-5 B) 4-5 C) 1 D) 1-3
A) 18 B) 12 C) 6 D) 24
A) FALSE B) TRUE
A) Prevent relapse into another psychotic episode B) Foster patients' medication compliance C) Minimize side effects of medication D) Develop more adaptive coping skills
A) several weeks after discontinuation of medication B) one year after discontinuation of medication C) directly after discontinuation of medication D) six months after discontinuation of medication
A) Artane B) Symmetrel C) Clozaril D) Thorazine
A) tardive dyskinesia more common B) weight gain more common C) increased effectiveness for positive, negative, and disorganized symptoms D) enhanced efficacy in treatment-resistant patients
A) Prochlorperazine B) Haloperiodol C) Risperidone D) Clozapine
A) Alcohol B) Anxiolitics C) Stimulants D) Anticonvulsants
A) Beta blockers B) Merperidine C) Halperiodol D) Alcohol
A) Anticonvulsants B) Nicotine C) Beta blockers D) Antacids
A) Beta blockers B) SSRIs C) Tricyclic antidepressants D) Alcohol
A) TRUE B) FALSE
A) Tobacco use B) Drug holidays C) Male gender D) Alcohol use
A) TRUE B) FALSE
A) Classic antipsychotic medications present less risk for the development of tardive dyskinesia than atypical antipsychotic medications. B) The more frequent the dose of the antipsychotic medication, the greater the risk for the development of tardive dyskinesia. C) High potency antipsychotic drugs present greater risk for the development of tardive dyskinesia. D) All antipsychotic drugs but Clozapine present a significant risk for the development of tardive dyskinesia.
A) Acute dystonia B) Akinesia C) Akathesia D) Ataxia
A) Gynecomastia B) Postural hypotension C) Agranulocytosis D) Neuroleptic Malignant Syndrome
A) TRUE B) FALSE
A) TRUE B) FALSE
A) block D2 receptors in the pituitary gland and decrease prolactin secretion. B) antagonize the normal dopamine-mediated inhibition of prolactin release. C) block D2 receptors in the pituitary gland and inhibit prolactin secretion. D) agonize the normal dopamine-mediated inhibition of prolactin release.
A) molecular structure B) neuroendocrine changes C) hungry hungry hippos D) receptor binding and DA turnover
A) Butyrophenones B) Phenothiazines C) Thioxanthenenes D) Sleepykoaladones
A) Weak; high; lower B) Potent; low; lower C) Potent; low; higher D) Weak; high; higher
A) Anhedonia B) Formal thought disorder C) Hallucinations D) Delusions
A) Endocrine disorders B) Neurological disorders C) Autoimmune diseases D) All of the above E) Metabolic disorders
A) Hallucinogens B) Opioids C) All of the above D) Stimulants E) Alcohol
A) FALSE B) TRUE
A) negative symptoms of Schizophrenia. B) positive symptoms of Schizophrenia. C) All of the above. D) disorganized symptoms of Schizophrenia.
A) blocking post-synaptic dopamine receptors and/or inhibiting dopamine release. B) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine release. C) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine reuptake. D) blocking post-synaptic dopamine receptors and/or inhibiting dopamine reuptake.
A) the drug reduces the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine. B) the drug increases the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine. C) the drug increases the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine. D) the drug reduces the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine.
A) increased rates of synthesis B) increased release of dopamine C) increased rates of firing D) increased tap dancing
A) aliphatics B) piperazines C) thioxanthenes D) piperideines
A) all of the above B) menstrual irregularity C) genecomastia D) galactorrhea
A) Benadryl (diphenhydramine) B) Symmetrel (amantadine) C) Inapsine (droperiodol) D) Artane (trihexphenidyl) E) Cogentin (benztropine)
A) TRUE B) FALSE
A) actual impact at the biological level B) comparative lack of EPS C) superior impact on positive symptoms D) polypharmacy
A) Clozaril B) Invega C) Abilify D) Haldol
A) Geodon B) Clorazil C) Seroquel D) Risperdal |